{"url_path":"/sec/bdtb/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/2041531/0001829126-26-005192-index.html","accession_number":"0001829126-26-005192","cik":"0002041531","ticker":"BDTB","issuer_name":"Bodhi Tree Biotechnology Inc","edgar_url":"https://www.sec.gov/Archives/edgar/data/2041531/0001829126-26-005192-index.html","primary_entity_key":"0002041531","primary_entity_name":"Bodhi Tree Biotechnology Inc"},"word_count":739,"has_tables":true,"body_markdown":"false\n2026\nQ2\n--09-30\n0002041531\n\n0002041531\n\n2025-10-01\n2026-03-31\n\n0002041531\n\n2026-05-14\n\n0002041531\n\n2026-03-31\n\n0002041531\n\n2025-09-30\n\n0002041531\n\n2024-10-01\n2025-03-31\n\n0002041531\n\n2026-01-01\n2026-03-31\n\n0002041531\n\n2025-01-01\n2025-03-31\n\n0002041531\n\nus-gaap:PreferredStockMember\n\n2025-09-30\n\n0002041531\n\nus-gaap:CommonStockMember\n\n2025-09-30\n\n0002041531\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-09-30\n\n0002041531\n\nus-gaap:RetainedEarningsMember\n\n2025-09-30\n\n0002041531\n\nus-gaap:PreferredStockMember\n\n2024-09-30\n\n0002041531\n\nus-gaap:CommonStockMember\n\n2024-09-30\n\n0002041531\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2024-09-30\n\n0002041531\n\nus-gaap:RetainedEarningsMember\n\n2024-09-30\n\n0002041531\n\n2024-09-30\n\n0002041531\n\nus-gaap:PreferredStockMember\n\n2025-10-01\n2026-03-31\n\n0002041531\n\nus-gaap:CommonStockMember\n\n2025-10-01\n2026-03-31\n\n0002041531\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-10-01\n2026-03-31\n\n0002041531\n\nus-gaap:RetainedEarningsMember\n\n2025-10-01\n2026-03-31\n\n0002041531\n\nus-gaap:PreferredStockMember\n\n2024-10-01\n2025-03-31\n\n0002041531\n\nus-gaap:CommonStockMember\n\n2024-10-01\n2025-03-31\n\n0002041531\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2024-10-01\n2025-03-31\n\n0002041531\n\nus-gaap:RetainedEarningsMember\n\n2024-10-01\n2025-03-31\n\n0002041531\n\nus-gaap:PreferredStockMember\n\n2026-03-31\n\n0002041531\n\nus-gaap:CommonStockMember\n\n2026-03-31\n\n0002041531\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-03-31\n\n0002041531\n\nus-gaap:RetainedEarningsMember\n\n2026-03-31\n\n0002041531\n\nus-gaap:PreferredStockMember\n\n2025-03-31\n\n0002041531\n\nus-gaap:CommonStockMember\n\n2025-03-31\n\n0002041531\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-03-31\n\n0002041531\n\nus-gaap:RetainedEarningsMember\n\n2025-03-31\n\n0002041531\n\n2025-03-31\n\n0002041531\n\nbdtb:OTCQBMember\n\n2026-03-31\n\n0002041531\n\nbdtb:OTCQBMember\n\n2025-09-30\n\n0002041531\n\nbdtb:BEECIncMember\n\n2026-03-31\n\n0002041531\n\nbdtb:BEECIncMember\n\n2025-09-30\n\n0002041531\n\n2024-03-01\n2024-03-31\n\n0002041531\n\nbdtb:XiaohangWangChiefExecutiveOfficerPresidentTreasurerAndDirectorMember\n\n2025-10-01\n2026-03-31\n\n0002041531\n\nbdtb:YunXiaSecretaryMember\n\n2025-10-01\n2026-03-31\n\n0002041531\n\nbdtb:OtherFoundersMember\n\n2025-10-01\n2026-03-31\n\n0002041531\n\nbdtb:CustomerAMember\n\n2025-10-01\n2026-03-31\n\n0002041531\n\nbdtb:CustomerBMember\n\n2024-10-01\n2025-03-31\n\n0002041531\n\nbdtb:CustomerAMember\n\n2026-01-01\n2026-03-31\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\nxbrli:pure\n\n \n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n \n\n**FORM 10-Q**\n\n \n\n**(MARK ONE)**\n\n☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**For the quarter ended March 31, 2026**\n\n \n\n☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**For the transition period from          to          **\n\n \n\n**Commission file number: 021-543738**\n\n \n\n**Bodhi Tree Biotechnology Inc.**\n\n(Exact Name of Registrant as Specified in Its Charter)\n\n \n\n**Delaware**\n \n**93-4908449**\n\n(State or other jurisdiction of\nincorporation or organization)\n \n(I.R.S. Employer\nIdentification No.)\n\n \n\n**4125 Blackhawk Plaza Circle, Suite 172**\n\n**Danville, CA 94506**\n\n(Address of principal executive offices)\n\n \n\n**Tel: (925)406-4528**\n\n(Issuer’s telephone number)\n\n \n\nCheck whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒   No ☐\n\n \n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒   No ☐\n\n \n\nIndicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\nLarge accelerated filer\n☐\nAccelerated filer\n☐\n\nNon-accelerated filer\n☒\nSmaller reporting company\n☒\n\n \n \nEmerging Growth Company\n☒\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐   No ☒\n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\n**Title of each class**\n** **\n**Trading Symbol(s)**\n** **\n**Name of each exchange on which registered**\n\nNot Applicable\n \nNot Applicable\n \nNot Applicable\n\n \n\nAs of May 14, 2026, 25,441,042 shares of common stock, par value $0.0001 per share, were issued and outstanding.\n\n \n\n \n\n \n\n \n\n \n\n \n\n**Bodhi Tree Biotechnology Inc.**\n\n \n\n**FORM 10-Q FOR QUARTER ENDED MARCH 31, 2026**\n\n \n\n**TABLE OF CONTENTS**\n\n \n\n \n \n \n \n**Page**\n\n**PART I – FINANCIAL INFORMATION**\n \n \n\n \n \n \n \n \n\n[Item 1.](#a_002)\n \n[Financial Statements](#a_002)\n \n1\n\n \n \n[Balance Sheets as of March 31, 2026 (Unaudited) and September 30, 2025](#a_003)\n \n1\n\n \n \n[Statements of Operation for the Three and six months ended March 31, 2026 and March 31, 2025 (Unaudited)](#a_004)\n \n2\n\n \n \n[Statements of Changes of Stockholders’ Equity for the Six Months ended March 31, 2026 and March 31, 2025 (Unaudited)](#a_005)\n \n3\n\n \n \n[Consolidated Statements of Cash Flows for the Six Months Ended March 31, 2026 and March 31, 2025 (Unaudited)](#a_006)\n \n4\n\n \n \n[Notes to Financial Statements (Unaudited)](#a_007)\n \n5\n\n[Item 2.](#a_008)\n \n[Management’s Discussion and Analysis of Financial Condition and Results of Operations](#a_008)\n \n12\n\n[Item 3.](#a_009)\n \n[Quantitative and Qualitative Disclosures About Market Risk](#a_009)\n \n17\n\n[Item 4.](#a_010)\n \n[Controls and Procedures](#a_010)\n \n17\n\n \n \n \n \n \n\n**PART II – OTHER INFORMATION**\n \n \n\n \n \n \n \n \n\n[Item 1.](#a_012)\n \n[Legal Proceedings](#a_012)\n \n18\n\n[Item 1A.](#a_013)\n \n[Risk Factors](#a_013)\n \n18\n\n[Item 2.](#a_014)\n \n[Unregistered Sales of Equity Securities and Use of Proceeds](#a_014)\n \n18\n\n[Item 3.](#a_015)\n \n[Defaults Upon Senior Securities](#a_015)\n \n18\n\n[Item 4.](#a_016)\n \n[Mine Safety Disclosures](#a_016)\n \n18\n\n[Item 5.](#a_017)\n \n[Other Information](#a_017)\n \n18\n\n[Item 6.](#a_018)\n \n[Exhibits](#a_018)\n \n19\n\n \n \n \n \n \n\n**SIGNATURES**\n \n20\n\n \n\ni\n\n \n\n \n\n**PART I – FINANCIAL INFORMATION**"}